NCT01886872: A trial that was reported late by National Cancer Institute (NCI)
This trial has reported, although it was 54 days late in doing so.
Full data
| Full entry on ClinicalTrials.gov | NCT01886872 |
|---|---|
| Title | A Randomized Phase III Study of Bendamustine Plus Rituximab Versus Ibrutinib Plus Rituximab Versus Ibrutinib Alone in Untreated Older Patients (≥ 65 Years of Age) With Chronic Lymphocytic Leukemia (CLL) |
| Results Status | Reported (late) |
| ACT or pACT? | This is what FDAAA officially calls a "probable Applicable Clinical Trial" |
| Start date | Jan. 15, 2014 |
| Completion date | Aug. 7, 2018 |
| Required reporting date | Aug. 7, 2019, midnight |
| Actual reporting date | Sept. 30, 2019 |
| Date last checked at ClinicalTrials.gov | Dec. 12, 2025 |
| Days late | 54 |